INTERCEPT-AD: DEVELOPMENT AND QUALIFICATION OF A HIGHLY SENSITIVE IMMUNOASSAY TO DETECT TOTAL SABIRNETUG (ACU193) IN HUMAN CSF

sabirnetug IV (ACU193 IV) - Acumen Pharma

https://alz.confex.com/alz/2024/meetingapp.cgi/Paper/94777

Hao Zhang1; Sarah Monsheimer2; Jennifer Gillies2; Derrick Johnson3; Nathan McOwen3; Erika N Cline1; Mahsan Rafizadeh1; Robert A Dean1; Jerome A Moore1; Jasna Jerecic1

Jun 20, 2024